E.C.M. RES.:
Management of the NSCLCin STADIO PRECOCEe METASTATICO

30 September 2026
IRCCS National Institute of Tumors - MILAN

TYPOLOGY

RES

FREE

DATE

30/09/2026

END DATE

30/09/2026
Sign in to join the course

Scientific rationale

The goal of this improvement table is to provide an update on important literature data, allowing participants to discuss the latest discoveries, contextualize them and really understand how they affect our daily practice. The different specialists involved will have the opportunity to interact with each other by sharing opinions on the main disputes concerning patient management with diagnosis of NSCLC, both in precocious stages of disease and in metastatic phase, with the final goal of mutual enrichment.

CONTRIBUTION

 

 

START
30 September 2026
END OF COURSE
30 September 2026
TYPOLOGY
RES
LOCATION
IRCCS National Institute of Tumors - MILAN
PARTICIPANTS
10
TARGETS
SURRGES

REFERENCE SPIPLINES:
ONCOLOGY - RADIOTERAPIA
ECM ID
752 - 483856
N. CREDITS RES
6,5
REGISTERING QUOTA
Free
E-MAIL
formazione@mondino.it
Studio Congressi s.r.l.
VAT: 01975530187
Reg. Companies of Pv: 01975530187
R.E.A.: 235792
Social Capital: € 260.000,00

Studio Congressi s.r.l. and Med Tech Science s.r.l.
Avenue of Liberty, 17 | 27100 Pavia (PV)
📞 +39.0382.21424 | +39.351.8055151
info@studio-congressi.com
medtechscience2@gmail.com
Code Recipient SDI BA6ET11

Med Tech Science Ltd.
VAT No: 02080160183
Reg. Pv: 02080160183
R.E.A.: 244029
Social Capital: € 100,000,00

Studio Congressi s.r.l. and Med Tech Science s.r.l.
Avenue of Liberty, 17 | 27100 Pavia (PV)
📞 +39.0382.21424 | +39.351.8055151
info@studio-congressi.com
medtechscience2@gmail.com
Code Recipient SDI BA6ET11

Studio Congressi s.r.l.
VAT: 01975530187
Reg. Companies of Pv: 01975530187
R.E.A.: 235792
Social Capital: € 260.000,00

Med Tech Science Ltd.
VAT No: 02080160183
Reg. Pv: 02080160183
R.E.A.: 244029
Social Capital: € 100,000,00